Gilead Sciences, Inc. (GILD)
Gilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need. It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology & oncology, and cardiovascular & inflammation as well as respiratory diseases. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera, Atripla, Truvada, Viread, Emtriva, Tybost, Vitekta, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, Hepsera, Zydelig, Letairis, Ranexa, Lexiscan, Cayston, Tamiflu, AmBisome and Macugen. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
|Market Price at 20-10-2017
|Price to Earnings Ratio
|Return on Equity (ROE)
Blog posts that reference Gilead Sciences, Inc.:
Thursday, July 09, 2015
In the May 2014 edition of Money magazine we compared Australia’s Top 10 stocks by market capitalisation against their global counterparts. We’ve just completed the process again: Australia’s Top 10 vs the world. You’ll be able to read our insights in Money’s August 2015 edition, on sale from 6 August).
To test our theory, we created a hypothetical $100,000 portfolio equally invested across the nine global stocks identified in the May 2014 article.
Including unrealised gains, dividends and currency gains, the stocks returned 29.9 per cent. By comparison the All Ords Accumulation Index returned 7.8 per cent. Skaffold’s global stocks outperformed the Index by 22.1 per cent, or 6.3 per cent if you exclude currency gains. That’s not too bad.
Thursday, January 08, 2015
Have you ever wondered what stocks your fellow members are researching?
Do other investors love Skaffold’s Summary page as much as you do?
Here are the highlights of what you loved to use in Skaffold in 2014, and what stocks were on your radar.
Friday, June 13, 2014
Once regarded as boring and fundamentally defensive, global healthcare stocks have re-emerged over the last few years as a powerhouse for future growth. Even though the S&P 500's healthcare sector is up over 20 per cent in the past year, it continues to offer more compelling entry points than its ASX-listed counterparts.
Given the strong run experienced by healthcare stocks globally, there are few – if any – absolute bargains left to pick off. Nevertheless, when you factor in their potential future upside, they still offer more compelling valuation propositions than their Aussie healthcare stocks. We found 9 future top performers in Skaffold Global.
Thursday, May 15, 2014
Australia’s top 10 stocks by market capitalisation – BHP Billiton (BHP), Commonwealth Bank (CBA), Rio Tinto (RIO), Westpac (WBC), ANZ, NAB, Telstra (TLS), Wesfarmers (WES), Woolworths (WOW) and CSL – are a solid group of companies that have, on balance, delivered strong returns for shareholders.
Are they positioned to continue delivering growth or do their global counterparts represent more attractive opportunities? We went inside Skaffold Global to find out.
Also consider this: you won’t find any global tech companies in the ASX 10. Pharmaceuticals, big oil and household products also fail to feature in our local market. To gain exposure to these global industries, you must expand your universe to the US and Europe.
Tuesday, April 15, 2014
Healthcare represents less than one per cent of the ASX, one of the world’s most dynamic growth sectors.
That’s why most Aussie healthcare stocks trade at what’s known as a ‘scarcity premium’.
Encompassing healthcare facilities, drug and biotechnology stocks, and medical equipment suppliers and manufacturers, the overall quality and performance of Australian healthcare stocks is impressive. Half of the top 10 achieved Skaffold’s preferred stock ratings of A1, A2, B1 and B2 based on their latest financial reports.
Despite a recent sell off, which has seen share prices of the top 10 fall, on average, 3% since late February, safety margins continue to be high, ranging between -15 and -75 per cent.
With the ‘scarcity premium’ enshrouding local healthcare stocks, we went in search of better healthcare value stocks offshore and found 6 standouts.
Friday, August 09, 2013
Over the last month more than 825 companies in Skaffold Global have updated to reflect their latest interim or full year financial results. Of those 825 stocks, 344 have seen their Skaffold Scores change.
Microsoft (MSFT) and biopharmaceutical manufacturer Bristol-Myers Squibb (BMY) have joined the US A1 club, alongside Boeing Company (BA), Mastercard (MA) and Eli Lilly (LLY). In Europe Hugo Boss (BOSS) fell from A1 to A2 whilst London-listed gambling company William Hill jumped from B2 (2011 full year to A1.